The result of the study on monkeys comes months after Clover began an early stage human trial in Australia in June, as global drug makers race to develop a safe and effective vaccine that can protect people from the COVID-19 pandemic that has killed almost 1 million people.
The company has previously said it expects to file for USA approval of the vaccine in December. Early clinical trial results also showed safety and an immune response after a single dose, according to the NIH news release. It's different from the other COVID-19 vaccine trials in several ways. Frontrunners Pfizer Inc, Moderna Inc and AstraZeneca Plc have already done the same.
A handful of other vaccines in the US - including shots made by Moderna and Pfizer - as well as drug developers in other countries are already in final-stage testing. Whereas Pfizer and Moderna's vaccines require two doses a few weeks apart. The J&J vaccine can also be stored in liquid form at refrigerator temperatures for three months, whereas two of the front-runner candidates must be frozen or kept at ultracold temperatures for long-term storage.
What Oracle stands to gain with TikTok buy
On August 6, Trump signed an executive order banning any USA transactions with ByteDance , set to take effect in 45 days. He argued that TikTok could funnel data from its 100 million American users to the Chinese government.
A fourth experimental vaccine developed by CanSino Biologics were approved to be used in the Chinese military in June. The trials have resumed in Britain, Brazil and South Africa, but remain on hold in the United States.
It will include significant representation among those over the age of 60, as well as minorities at disproportionate risk of becoming infected, including Black, Hispanic, American Indian and Alaskan Native peoples, according to a statement.
A fourth Phase 3 clinical trial in the U.S. to evaluate an investigational Covid-19 vaccine was underway and has started enrolling adult volunteers, the National Institutes of Health (NIH) announced. The price of the liquid solution exported overseas will be about half the cost of the full vaccine, the CEO added. The trial sites are part of an NIAID-supported COVID-19 Prevention Network.
"We're approaching these countries to find out what is the status of their vaccine and whether they are willing to enter into a partnership with us in one form or another either through trials or through manufacture in our country", he said. He said that scenario is unlikely, though.
The pharma giant's candidate involves a single-dose vaccine, which could help trials move faster than competitors as researchers will be able to measure efficacy after one shot rather than two.